Has Ann Silk, MD received payments from drug or device companies?

Yes. Drug and device makers reported $101,765 in general payments to Ann Silk, MD across 118 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ann Silk, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ann Silk, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ann Silk, MD

Medical Oncology · Boston, MANPI 1477717106

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $81,215 of the $101,765 with a category attached, or 79.8%. 11 manufacturers reported payments, led by Merck at 31.6% of the total. 2025 is the largest year on record at $56,573, 4.4 times the $13,001 reported in 2019.

$101,765in general payments, 2019–2025

Across 118 payments — averaging $862.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$32K
Regeneron Healthcare Solutions, Inc.$28K
Sun Pharmaceutical Industries Inc.$28K
Sanofi$5K
E.r. Squibb & Sons, L.L.C.$3K
EMD Serono, Inc.$2K
plus $4K from 5 others

$1,027,940in research payments, 2019–2025

Across 82 payments — averaging $12,536 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$643K
Regeneron$236K
Biohaven Pharmaceuticals, Inc.$131K
Clinigen, Inc.$18K

What the payments were for

Consulting fees$81,21580%
Speaking & faculty fees$2,4002%
Travel & lodging$13,91614%
Food & beverage$4,2344%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	43	$32,112
Regeneron Healthcare Solutions, Inc.	32	$28,192
Sun Pharmaceutical Industries Inc.	26	$27,863
Sanofi	1	$5,000
E.r. Squibb & Sons, L.L.C.	2	$2,550
EMD Serono, Inc.	4	$2,462
Immunocore Limited	1	$2,400
Clinigen, Inc.	4	$537
Pfizer	2	$285
Regeneron	2	$218
Iovance Biotherapeutics, Inc.	1	$145

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LIBTAYO$32,986
Unloxcyt$26,965
BAVENCIO$2,433
KIMMTRAK$2,400
OPDIVO$1,725
KEYTRUDA$915
Proleukin$448
LORBRENA$150
Amtagvi$145

How this compares

$101,765 in reported general payments places this provider in the 85th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts →

Medicare billing

Part B allowed, 2024

$72,067

Medicare patients

222

Services billed

492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Levothyroxine Sodium	25	$340

Paid to pharmacies, not to this prescriber.

Other medical oncology in Boston

George DemetriBoston$1.6M
Keith FlahertyBoston$932K
Alicia MorgansBoston$690K
Pasi Antero JanneBoston$458K
Robert HaddadBoston$451K
Irene GhobrialBoston$431K
Joaquin Bellmunt MolinsBoston$415K
Jeremy AbramsonBoston$334K
Justin GainorBoston$324K
Narjust FlorezBoston$324K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →